Literature DB >> 13832218

Results of a study of the reactogenic and immunogenic properties of live anti-poliomyelitis vaccine.

A A SMORODINTSEV, E F DAVIDENKOVA, A I DROBYSHEVSKA YA, V I ILYENKO, N E GOREV, L M KURNOSOVA, T E KLYUCHAREVA.   

Abstract

The authors have studied the harmlessness and immunogenic properties of live poliomyelitis vaccine made in Leningrad from Sabin strains of low pathogenicity for monkeys. More than 20 000 children of pre-school (6 months to 3 years) and school age (7-14 years) were each given 100 000 tissue-culture infective doses of virus of types 1, 2 and 3, injected either in three stages at monthly intervals in the form of monovaccines, or in two stages, a monovaccine of type 1 being followed after a month's interval by injection of a divalent vaccine of types 2 and 3. The vaccination caused no symptoms of lesions of the central nervous system or other organs. In the blood of the inoculated children there was a regular build-up of virus-neutralizing antibodies to the serotypes mentioned, the intensity of which depended on the antibody level before vaccination and was in a constant relationship to the multiplication of the virus in the intestinal canal. The antibody titre was maintained at high levels for 6-9 months after immunization and fell a little after 12-18 months. The vaccinal virus is easily transferred from vaccinated children to contact groups, which are gradually vaccinated by this natural means.Lengthy and numerous passages of vaccinal strains through the intestinal canal of normal, susceptible children showed that strains may periodically appear which have a higher neurotropic activity for monkeys. This activity, however, did not increase in subsequent passage and returned to the initial level.

Entities:  

Keywords:  POLIOMYELITIS/immunology

Mesh:

Substances:

Year:  1959        PMID: 13832218      PMCID: PMC2537891     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Properties and behavior of orally administered attenuated poliovirus vaccine.

Authors:  A B SABIN
Journal:  J Am Med Assoc       Date:  1957-07-13

2.  Characteristics and genetic potentialities of experimentally produced and naturally occurring variants of poliomyelitis virus.

Authors:  A B SABIN
Journal:  Ann N Y Acad Sci       Date:  1955-09-27       Impact factor: 5.691

3.  Immunization of infants with living attenuated poliomyelitis virus; laboratory investigations of alimentary infection and antibody response in infants under six months of age with congenitally acquired antibodies.

Authors:  A FLACK; K HUMMELER; A D HUNT; G A JERVIS; H KOPROWSKI; T W NORTON; J STOKES
Journal:  J Am Med Assoc       Date:  1956-12-01

4.  Present status of attenuated live-virus poliomyelitis vaccine.

Authors:  A B SABIN
Journal:  J Am Med Assoc       Date:  1956-12-29
  4 in total
  4 in total

1.  Virus excretion after mass vaccination with attenuated polioviruses in Hungary.

Authors:  I DOMOK; E MOLNAR; A JANCSO
Journal:  Br Med J       Date:  1961-05-20

2.  Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum.

Authors:  M L Tanzi; P Colotto; M Vignali; P Affanni; U Bracchi; E Bellelli
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

3.  Factors affecting the efficacy of live poliovirus vaccine in warm climates. Efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda.

Authors:  I Dömök; M S Balayan; O A Fayinka; N Skrtić; A D Soneji; P S Harland
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

Review 4.  Why are vaccines against many human viral diseases still unavailable; an historic perspective?

Authors:  Gregory A Tannock; Hyunsuh Kim; Lumin Xue
Journal:  J Med Virol       Date:  2019-10-03       Impact factor: 2.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.